🔺 What to do when markets are at an all-time high? Find smart bargains, like these.See Undervalued Shares

This pharma stock could easily gain 20% next year, Jefferies says

Published 11/12/2024, 21:10
© Reuters.
GILD
-

Investing.com -- This pharma stock could see its stock gain 20% in 2025, driven by the anticipated launch of its long-acting HIV prevention therapy, analysts estimate.

Gilead Sciences Inc (NASDAQ:GILD) could rise to $110 in 2025, Jefferies said, after it unveiled its robust HIV treatment pipeline at an analyst meeting, ranging from weekly pills to six-month injections.

A key focus is the summer 2025 launch of a six-monthly injectable HIV pre-exposure prophylaxis (PrEP) therapy, which analysts estimate could tap into a $2-5 billion total addressable market (TAM).

The therapy, known as LEN, is expected to achieve better compliance and adherence compared to existing treatments, including Gilead’s own Descovy and generic Truvada. LEN has already been incorporated into the 2024 International Antiviral Society-USA guidelines, which could accelerate its market penetration.

LEN’s pricing dynamics also bode well for Gilead, with analysts predicting lower rebates compared to Descovy, whose gross-to-net margin is currently around 50%. Additionally, LEN could attract patients transitioning from generic Truvada, further expanding its market potential.

Analysts noted that reimbursement logistics for LEN will largely bypass the burdensome “buy-and-bill” system. Instead, 70-80% of prescriptions are expected to use a streamlined specialty pharmacy process, simplifying access for both patients and providers.

Gilead currently holds 45% of the U.S. PrEP market, primarily through Descovy, with generics and rival injectables from GSK comprising the remainder. The company expects to grow its PrEP market share to over 60% by 2030, supported by increased adherence rates projected to exceed 80%, compared to the current 50-55%.

Future upside could come from Gilead’s plans for a once-yearly injectable PrEP formulation. Phase III trials for this version are slated to begin in 2025, with a potential regulatory filing by 2027. While this development is not factored into current market expectations, analysts see it as a modest long-term growth driver.

Gilead’s focus on innovative HIV treatments and its strategic approach to reimbursement and compliance set the stage for substantial revenue growth, analysts concluded.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.